HDMA Qs and As on the Drug Supply Chain Security Act (DSCSA)  
VERSION 3.0  
NOVEMBER 2015

This document, the HDMA Qs and As on the Drug Supply Chain Security Act (DSCSA), has been prepared by the Healthcare Distribution Management Association (HDMA) in consultation with its Traceability Implementation Work Group (Work Group). This document discusses how the DSCSA applies to several areas of wholesale distributor operations.

These Qs and As should be reviewed with reference to the DSCSA and Food and Drug Administration’s (FDA) implementing regulations and guidance. They should also be considered in conjunction with other documents provided by HDMA such as the Transaction Scenarios, ASN Guidelines, ASN Business Examples, ASN Exceptions Guidelines and other documents.

These materials are not legal advice and are based on evolving requirements. As such, they may change as the Food and Drug Administration (FDA) issues guidance and regulations implementing the DSCSA. Each company must make its own business decisions about DSCSA implementation. Please consult your operations, regulatory and information technology staff, consultants and legal counsel as well as your trading partners for further implementation guidance.

NOTE 1: This Version 3.0 October 2015 is a revision of the Version 2.0 March 2015 Qs and As. We have revised this document based on our evolving understanding of the DSCSA and additional questions we have received as wholesale distributors and their supply chain partners continue to implement the statutory requirements. Version 3.0 does not change the intent or interpretation of the questions or answers from that of the prior versions. Rather, Version 3.0 is an update primarily to add additional Qs and As. Version 3.0 also contains a limited number of modifications to certain questions for clarity.

NOTE 2: On December 24, 2014, FDA issued a guidance document entitled, “DSCSA Implementation: Product Tracing Requirements – Compliance Policy” (“compliance policy guidance”).\(^1\) In the compliance policy guidance, FDA announced that it would exercise enforcement discretion with respect to the DSCSA’s product tracing requirements until May 1, 2015 for manufacturers, wholesale distributors and repackers. This enforcement discretion did not extend to other requirements in section 582 of the FD&C Act, such as verification related to suspect and illegitimate product (including quarantine, investigation, notification and recordkeeping) and requirements related to engaging in transactions only with authorized trading partners.

Accordingly, although some of the responses below identify a statutory implementation date of January 1, 2015, we recognize that FDA has stated that it intends to exercise “enforcement discretion” and does not intend to begin enforcing the product tracing requirements of the DSCSA until May 1, 2015. We have added an asterisk (*) to those Qs and As below related to product tracing requirement, that though effective on January 1, 2015, are subject to FDA’s exercise of enforcement discretion until May 1, 2015. However, the May 1, 2015 enforcement discretion extension does not apply to all sections of DSCSA, therefore January 1, 2015 remains the implementation date for some sections.

As of May 1, 2015, the enforcement discretion expired and the product traceability requirements applicable to manufacturers, wholesale distributors and repackers on January 1, 2015 are in effect and enforceable.

**NOTE 3:** On July 1, 2015, FDA issued a guidance document entitled, “DSCSA Implementation: Product Tracing Requirements for Dispensers– Compliance Policy.” (“Dispenser Compliance Policy Guidance”). The Dispenser Compliance Policy Guidance announced that FDA would exercise enforcement discretion until November 1, 2015 with respect to the DSCSA’s product tracing requirements that would otherwise be applicable to dispensers on July 1, 2015. Specifically, the agency stated, “FDA does not intend to take action against dispensers who, prior to November 1, 2015, accept ownership of product without receiving the product tracing information, as required by section 582(d)(1)(A)(i) of the FD&C Act.” FDA emphasized the limited scope of this enforcement discretion, stating: “this compliance policy does not extend to transactions in which dispensers must provide the subsequent owner with product tracing information, including transaction history, as required by section 582(d)(1)(A)(ii).” Subsequently, on October 28, 2015, FDA issued a guidance document entitled, “DSCSA Implementation: Product Tracing Requirements for Dispensers – Compliance Policy (Revised)” ("Revised Dispenser Compliance Policy Guidance").¹ The Revised Dispenser Compliance Policy Guidance announced that FDA would exercise enforcement discretion until March 1, 2016 with respect to DSCSA’s product tracing requirements that would otherwise be applicable to dispensers on November 1, 2015.

Because the traceability requirements for dispensers did go into effect on July 1, HDMA uses this original statutory deadline in any questions or answers described below, recognizing that FDA has stated that it will not begin enforcing those requirements until March 1, 2016.

---

Index of Questions

I. DEC 31, 2014 COMPLIANCE POLICY GUIDANCE
II. GENERAL
III. SALABLE RETURNS
IV. NONSALABLE RETURNS
V. SUSPECT AND ILLEGITIMATE PRODUCT
VI. 340b QUESTIONS
VII. DISPENSER RELATED QUESTIONS
VIII. EXEMPT PRODUCTS
IX. DATA-TRANSMISSION AND ASN-RELATED QUESTIONS
X. EXCEPTIONS TO TRANSACTION DATA REQUIREMENTS
XI. GRANDFATHERED PRODUCT

I. DEC 31, 2014 COMPLIANCE POLICY GUIDANCE

1. Does the compliance policy guidance released by FDA on December 31, 2014 extend the deadline to implement DSCSA?

No, it does not. FDA has granted enforcement discretion for one part of the DSCSA, which means that the law is still in effect and should be implemented. However, FDA is intending to exercise enforcement discretion for trading partners that meet the description in the policy guidance. For additional information, see Note 1 above in the cover page.

2. Does the compliance policy guidance grant enforcement discretion for implementation of the entire DSCSA until May 1, 2015?

No, the compliance policy guidance only affects the data transmission portion (TI/TH/TS) of the DSCSA. It does not change or modify the implementation dates or deadlines of any other DSCSA requirements including but not limited to submitting licensure registration, suspect and illegitimate product, etc. For additional information, see Note 1 above in cover page.

3. Who does the compliance policy guidance released by FDA on December 31, 2014 apply to?

The compliance policy guidance only applies to manufacturers, wholesale distributors and repackagers. For additional information, see Note 1 above in the cover page.
II. **GENERAL**

4. **Will wholesale distributors be required to provide lot number (in TI and TH) to downstream trading partners starting January 1, 2015?**

Under DSCSA, a “direct purchase wholesale distributor” [i.e., one that acquired the product directly from the manufacturer, exclusive distributor or repackager (in the case of a repackager, only if the repackager purchased directly from the manufacturer)] is NOT required to pass lot number. If a wholesale distributor is not a “direct purchase wholesale distributor,” it must pass lot number as part of TI and TH when transferring ownership of the product. For additional information see the separate HDMA ASN Business Examples Document.

5. **What transaction data (TI/TH/TS) needs to be passed in the following scenario: Affiliate Manufacturer to Affiliate Repacker to Wholesale Distributor?** In this scenario, one affiliate manufactures the finished product and sells to the other affiliate, who is the repacker. The repacker packs into NEW finished product packaging and sells to wholesale distributors.

First, because the manufacturer and repacker are affiliates, the manufacturer’s transfer of product to the repacker qualifies for an exemption from the definition of “transaction.” Thus, the manufacturer would not have to pass TI/TH/TS to the repacker. Second, the repacker would have to pass TI/TH/TS to the wholesale distributor, with TH starting with the repacker. Finally, DSCSA § 582(c)(1)(A)(ii) [21 U.S.C. 360eee-1(c)(1)(A)(ii)] creates the “direct purchase option” under which purchases made directly from (i) the manufacturer, (ii) the exclusive distributor, or (iii) a repacker that purchased direct from the manufacturer, qualify for abbreviated TI and TH. Under this transaction scenario, because the wholesale distributor is purchasing from a direct-purchase repacker, the wholesale distributor would not have to include the lot number in TI or TH, and would not have to include the transaction date or shipment date (associated with its acquisition of product from the repacker) in TH.

6. **How should wholesale distributors address the gap between the requirement for wholesale distributors to provide TI/TH/TS on January 1, 2015, and the requirement for dispensers to receive it on July 1, 2015?**

Trading partners will need to decide how they wish to address this gap as a business matter.

7. **Does shipment date need to be included in TI and TH for compliance with DSCSA?**

Shipment date is only required to be included in TI/TH when the shipment date is more than 24 hours after the transaction date.
8. For a given transaction, when does ownership transfer take place?

Supply agreements may specify different points for actual transfer of title of goods, e.g., title may pass when goods leave the shipper’s dock, when the goods are delivered to the buyer’s dock, or when the buyer opens the truck, inspects the delivery and accepts it. “Transaction” is defined in DSCSA as “the transfer of product between persons in which a change of ownership occurs.” § 581(24)(A); 21 U.S.C. § 360eee(24)(A). HDMA has recommended that FDA permit trading partners to use any commercially reasonable and supportable transaction date.

9. Can you provide clarification on transaction date and shipment date as it relates to the ASN and packing list?

For the purposes of the DSCSA, transaction date is the date of ownership transfer as recognized by the trading partners. The DSCSA does not define specifically how a company is to determine transaction date. HDMA has recommended that FDA permit trading partners to use any commercially reasonable and supportable transaction date in whatever document is sent, whether the ASN or a packing slip. In the ASN, the segment containing the transaction date is the Beginning Segment Date or “BSN”.

10. When a seller prepares a packing list, the shipment date is unknown. It might ship the same day or within the next couple of days. Which date should be printed on the packing list? After the ASN is sent, the seller has an actual ship date. Does the ship date in the ASN need to match the date on the packing list? If so, how can this be achieved?

The transaction date must be included on whichever document/documents that the seller designates to satisfy the DSCSA requirement to pass TI/TH/TS (whether packing slip, ASN or other). DSCSA does not require that the dates used on the packing slips and ASNs match, nor does HDMA offer any guidance on this.

11. FDA recognizes 10-digit NDC numbers, yet certain customers require 11 digit or 12 digit NDC numbers for a variety of business reasons. What NDC number should be included in the TI/TH in order to comply with the DSCSA requirements?

Trading partners should use the same NDC number (whether 10 or 11 digits) when placing orders and sending ASN’s.

12. Is there a definition of “co-licensed partner”?

The DSCSA definition of “manufacturer” includes a “co-licensed partner” of the holder of the drug product’s New Drug Application (NDA), Abbreviated New Drug Application (ANDA) or Biologics License Application (BLA), or the NDA/ANDA/BLA holder’s affiliate. However, the DSCSA does not
otherwise define “co-licensed partner.” The term is commonly used in industry and has been defined in the laws of many states. These definitions may help inform how FDA should interpret “co-licensed partner” for DSCSA purposes. To help inform FDA’s interpretation, several supply chain members have communicated to FDA the view that “an entity, including a private label distributor, that receives product from the NDA/ANDA/BLA holder pursuant to a license or similar contractual agreement that confers a right on the entity to sell the product through its distribution channels is a co-licensed partner of the NDA/ANDA/BLA holder and therefore meets the DSCSA definition of ‘manufacturer’.”

To date, FDA has not commented on this view.

13. What responsibility for the TI/TH/TS data does a pharmacy have if it sells or merges its pharmacy business, including its inventory of products covered by the DSCSA, to or with another pharmacy? Is the sale of a pharmacy to another that includes the products in the seller’s inventory, a “transaction” under the DSCSA? What responsibility does the new purchasing pharmacy have for the existing data of products previously purchased and sold by the selling pharmacy?

There are two considerations for the data involved:

  a) When a selling pharmacy is sold to a buying pharmacy, and the sale includes the seller’s existing inventory of products, is that sale a “transaction” under the DSCSA that would require the selling pharmacy to pass TI/TH/TS to the buying pharmacy?

  and

  b) When a pharmacy is sold to or merges with another pharmacy, what is the appropriate disposition of the data the selling or merging pharmacy has had to maintain for six years for each product transaction?

Generally, TI/TH/TS data must be provided for any “transaction” (i.e., change in ownership) of a covered drug product. However, the DSCSA explicitly exempts from the definition of “transaction” (and thus from the requirements to pass or receive TI/TH/TS) any “distribution of a product pursuant to the sale or merger of a pharmacy or pharmacies.” § 581(24)(8)(ix) Therefore, the selling or merging pharmacy is not required to provide TI/TH/TS for the sale of the drugs in its inventory that are part of the sale of its business to the acquiring pharmacy.

---

Under the DSCSA, the selling pharmacy would have been required to receive TI/TH/TS data for all product transactions after July 1, 2015 (though FDA granted enforcement discretion until November 1, 2015) and that pharmacy must maintain those data for six years. As discussed above, the DSCSA exempts the selling pharmacy from passing TI/TH/TS for the inventory it sells in a merger or other corporate sale of its business to another pharmacy. The statute does not specifically address what should happen to the selling pharmacy’s existing transaction data for its acquisition of product. We believe the most prudent reading of the DSCSA is that the selling pharmacy should share with the purchasing pharmacy the historical TI/TH/TS data it received so that the purchasing pharmacy may maintain the data for six years from the original transaction date. If the selling pharmacy was using a third-party to maintain its data, the seller should inform the buying pharmacy on how to access that historical data. Without possession of or access to the historical TI/TH/TS for the inventory it acquired in the corporate transaction, the purchasing pharmacy might not be able to comply with DSCSA requirements regarding, among other things, investigations of suspect and illegitimate product, and requests for verification.

14. How can I find out if my trading partner is an “authorized trading partner”?

DSCSA requires each supply chain member to ensure that it buys products from and sells products to only “Authorized Trading Partners.” A manufacturer is considered authorized if it is registered with the FDA as a drug establishment. FDA maintains a searchable database that can be checked to confirm a drug manufacturer’s registration status. See http://www.accessdata.fda.gov/scripts/cder/drls/default.cfm [The DSCSA defines “manufacturer” to include an NDA/ANDA/BLA holder. If an application holder does not physically produce product, then FDA does not permit the company to register its facility. Industry stakeholders have proposed that application holders – as well as other entities that would appear to function for DSCSA purposes as manufacturers, yet are not permitted by FDA to register – be considered by FDA to be “authorized” for DSCSA purposes.4 The FDA has not yet commented on the stakeholders’ recommendations.]

A wholesale distributor is considered authorized if it has a valid state license (or federal license if the state does not issue licenses) and has reported its current state licenses to the FDA. You can check state licensing websites for licensure status. For most states this information is included in the state Board of Pharmacy’s website. These websites usually make available to the public the licensed entity’s name and license number. FDA has provided a listing of state licensing authority information here: http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm281446.htm You may also ask that your trading partner provide documentation of their Authorization status, such as by providing a copy of a license certificate.

---

The DCSA also requires wholesale distributors to report licensure and certain other information for each facility annually to FDA and FDA must make some of that information publicly available. See §503(e)(2). Licensure reporting data are now searchable on FDA’s website at http://www.accessdata.fda.gov/scripts/cder/wdd3preporting/index.cfm. The licensure information searchable from this database may be another route for determining authorization status information.

The supply chain has proposed to FDA that this publicly available information should be allowed to be used to verify authorization status. FDA has not yet responded to this recommendation. A third-party logistics provider, like a wholesale distributor discussed above, is considered authorized if it has a valid state license (or federal license if the state does not issue licenses) and has reported its current state licenses to the FDA. § 584(a)-(b). You can check FDA’s database for licensure status at http://www.accessdata.fda.gov/scripts/cder/wdd3preporting/index.cfm. As discussed above, FDA has not formally stated whether this information can be used to verify authorization status.

A dispenser is considered authorized if it/he/she has a valid license under state law. Trading partners can check state-maintained databases to confirm licensure status, or, as above, ask the dispenser to provide a copy of the applicable license certificate. Supply chain partners have also requested that FDA recognize the limited instances in which dispensers should be “authorized” but are not necessarily licensed by the state. Certain Department of Defense facilities are one example.

It is also recommended that each supply chain partner check with their own advisors and regulatory counsel as to the most appropriate method for confirming authorization status for their individual business.

III. SALABLE RETURNS

15. What is a “return” under the Drug Supply Chain Security Act (DCSA)?

“Return” as used under the DCSA means providing product to the authorized immediate trading partner from whom such product was purchased or received, or to a returns processor or reverse

---

logistics provider for handling of such product. §581(17). Sending product to a trading partner from whom the product was not purchased is a new transaction and not a return. As discussed in Question 16 below, the DSCSA provides streamlined procedures for certain product movements that meet the definition of a “return.”

16. How does DSCSA address salable returns to a wholesale distributor?

Beginning January 1, 2015*, until November 27, 2019, a wholesale distributor may accept a return from a dispenser or repacker pursuant to the terms and conditions of an agreement between the parties. The parties may agree that the dispenser or repacker does not need to provide TI, TH and/or TS with the returns it makes to its wholesale distributor supplier. The wholesale distributor may resell the returned product without providing TH that reflects the prior sales. For any subsequent resale of the returned product, the TH begins with the wholesale distributor that accepted the return. §582(c)(1)(B)(i)(I).

After November 27, 2019, a wholesale distributor may accept returned product from a dispenser or repacker only if it can associate the returned product with the TI and TS associated with the original sale of that product to the dispenser/repackager. For all transactions after that date, the TH shall begin with the wholesale distributor that accepted and verified the returned product. However, the TH need not include transaction dates if it is not reasonably practicable to obtain those dates. §582(c)(1)(B)(i)(II).

17. Are TI/TH/TS required if a “secondary distributor” is returning a drug product to a direct purchase distributor? Can the direct purchase distributor resell these returned products?

This transaction is a return under the DSCSA, but because it is from a wholesale distributor rather than from a dispenser or repacker, the return is not eligible for streamlined treatment under the DSCSA. Therefore, the return from the “secondary distributor” to the direct purchase distributor constitutes an independent transaction that requires full transaction data. The “secondary distributor” must provide TI/TH/TS to the direct purchase distributor. And yes, while the direct purchase distributor may resell the product, the DSCSA is unclear as to whether the TH for the subsequent sale may begin with the direct purchase distributor or whether the direct purchase distributor must show the previous sale to and return from the “secondary distributor,” as well as all prior TH back to the original manufacturer.

18. Are TI/TH/TS required if a direct purchase distributor is returning drug product to an exclusive distributor? Can the exclusive distributor resell the drug product? If so, what TI/TH/TS does the exclusive distributor have to provide with a subsequent resale of the product?

This transaction is a return under the DSCSA, because it is from a wholesale distributor to the party (the exclusive distributor) from whom it acquired the product. However, the return is not
eligible for streamlined treatment under the DSCSA applicable to returns accepted by wholesale distributors from a dispenser or repackager. Therefore, the return from the wholesale distributor to the exclusive distributor constitutes an independent transaction that requires full transaction data. The wholesale distributor must provide TI/TH/TS to the exclusive distributor.

And as in Question 14 above, while the exclusive distributor can resell the product, the DSCSA is unclear as to whether the TH for the subsequent sale begins anew with the exclusive distributor or whether it must show the previous sale to and return by the wholesale distributor, as well as all prior TH back to the original manufacturer.

19. When a dispenser changes wholesale distributor suppliers, can the new wholesale distributor (Distributor Y) accept as a return product that was originally sold to the dispenser by its initial distributor (Distributor X)?

Distributor Y can accept product from the dispenser, but the product would not be treated as a “return” under the DSCSA and thus would not be entitled to the streamlined treatment described in Question 13. The sale from the dispenser to Distributor Y would represent a new transaction for which the dispenser would have to pass TI/TH/TS (and, technically, be licensed as a wholesale distributor because it is engaging in wholesale distribution). Further, if Distributor Y makes a subsequent sale of that product, the TH it passes would need to include the transaction with the dispenser, as well as all other prior transactions. If a return is nonsalable, TI/TH/TS would not need to be passed.

20. Does the DSCSA define what a returns processor is? Can a returns processor handle both salable and nonsalable products?

Yes. The DSCSA defines returns processors (or “reverse logistics provider”) as “a person who owns or operates an establishment that dispositions or otherwise processes salable or nonsalable product received from an authorized trading partner such that the product may be processed for credit ... or disposed of for no further distribution.” §581(17). Thus, the returns processor is allowed to handle both salable product and nonsalable product under the DSCSA. However, there is no provision that permits a returns processor to sell the returned product. As a result, if the returns processor sells the returned goods, it would be acting as a wholesale distributor and would have to comply with the traceability and licensure requirements applicable to a wholesale distributor (including receiving and passing full TI/TH/TS and including TH for the product’s prior transactions).

21. Is a returns processor required to receive or provide TI/TH/TS? Is there a distinction between salable and nonsalable product?

In most circumstances, a returns processor would not be required to receive or pass TI/TH/TS.
The DSCSA defines returns processor (or reverse logistics provider) as “a person who owns or operates an establishment that dispositions or otherwise processes salable or nonsalable product received from an authorized trading partner such that the product may be processed for credit to the purchaser, manufacturer, or seller or disposed of for no further distribution.” § 581(18). While not explicit in this definition, the returns processor generally does not take ownership of the returned product and, therefore, would not be required to receive TI/TH/TS. Furthermore, for nonsalable product, TI/TH/TS do not need to be passed.

If the returns processor takes ownership of a salable return and resells the drugs, the returns processor would be treated as a wholesale distributor and would have to both receive and pass TI/TH/TS. If the returns processor receives a salable return from the original purchaser (“Buyer #1”) -- but does not take ownership of the drugs -- and then, at the owner’s (“Seller”) request ships the drugs to a new purchaser (“Buyer #2”), then the Seller will need to provide TI/TH/TS to Buyer #2. [NOTE: Whether Seller must receive TI/TH/TS from Buyer #1 when Buyer #1 returns the drugs (through the returns processor) depends on many factors, including whether the Seller is the manufacturer or wholesale distributor, and whether Buyer #1 is a direct purchase wholesale distributor, non-direct-purchase wholesale distributor or dispenser. Please consult with your regulatory counsel for details specific to your situation.]

22. What TH must a wholesale distributor provide when it resells returned product that it originally sold prior to January 1, 2015*, but seeks to resell after that date?

The answer to this question is not affected by when the product was initially sold by the wholesale distributor. A wholesale distributor may accept returns from a dispenser or repackager to whom it sold the product pursuant to the terms and conditions of an agreement between the parties. Starting January 1, 2015*, the TH the wholesale distributor provides for any subsequent sale of that product does not have to reflect the prior transactions. For any resale, the TH begins with the wholesale distributor that accepted the return.

23. Can a wholesale distributor accept returns from a repackager, and if so, what TI/TH/TS must be passed by the repackager on the return transaction, and what TI/TH/TS must be passed by the wholesale distributor if and when it resells the product?

See Question 13 above regarding the streamlined procedure under the DSCSA that permits a wholesale distributor to accept returns from a repackager (or dispenser) to whom it sold the product pursuant to the terms and conditions of an agreement between the parties. The TH the wholesale distributor provides for any subsequent sale of that product does not have to reflect the prior sale to or return by the repackager. For any resale transactions, the TH would begin with the wholesale distributor that accepted the return.

However, if the repackager has repackaged the product (e.g., with new labeling, new lot number and new NDC number), this would appear to be a new product, which, we believe, would not
qualify as a “return” under DSCSA; rather, the repackager’s shipment back to the wholesale distributor would constitute a new transaction involving a new product. Moreover, if the wholesale distributor sought to sell the indirectly sourced repackaged product, it would have to pass full TI/TH/TS tracing back to the original sale by the manufacturer (which would present a significant challenge).

24. What if a wholesale distributor ships a product to a licensed practitioner and the licensed practitioner returns the product? What TI/TH/TS would the wholesale distributor need to provide on a subsequent resale of the returned product?

The DSCSA includes licensed practitioners within the definition of “dispenser,” but provides that licensed practitioners are exempt from complying with the traceability requirements generally applicable to dispensers. Although the statute is far from clear, we believe returns by licensed practitioners would be treated in the same manner as returns from any other dispenser. That is, a licensed practitioner could return product to the wholesale distributor from whom he/she purchased the product (pursuant to an agreement between the parties) without having to provide TI/TH/TS, and the wholesale distributor could then resell the product by providing TH that started with the wholesale distributor’s resale.

25. Does the DSCSA affect the return of product from wholesale distributors back to the manufacturer? Or 3rd party processors? If so, what information has to be passed?

The DSCSA provides that a wholesale distributor may return nonsalable product to the manufacturer from whom it acquired the product without having to pass TI/TH/TS. Such return can be made directly to the manufacturer or through a 3rd party returns processor.

The DSCSA does not specifically address returns of salable product from a wholesale distributor to the manufacturer. Accordingly, at least arguably, such return transactions would not be exempt from the traceability requirements and the wholesale distributor would have to pass TI/TH/TS to the manufacturer (whether directly or through a 3rd party returns processor). The content of the TH would depend on the prior transactions associated with the product. [NOTE: If the product is sent back to the manufacturer prior to the wholesale distributor formally taking ownership of the product, then the movement of goods would not constitute a transaction and thus the wholesale distributor would not need to pass TI/TH/TS when shipping the goods back to the manufacturer.]
IV. NONSALABLE RETURNS

26. What requirements apply to nonsalable returns to or from a wholesale distributor?

Under the DSCSA, a wholesale distributor may return a nonsalable product to the manufacturer or repackager, to the wholesale distributor from whom such product was purchased, or to a person acting on behalf of such a person, such as a returns processor, without providing TI/TH/TS.

Further, the DSCSA does not require a dispenser to provide TI/TH/TS when it returns nonsalable product to the wholesale distributor from whom it acquired the product. Implicitly, this means that the wholesale distributor is relieved of any requirement to receive TI/TH/TS when accepting the nonsalable returned goods from the dispenser. Further, we believe this transfer may be outside the scope of the DSCSA because when a drug is nonsalable, it is not for “administration to a patient.” If a drug is not for administration to a patient, it does not meet the definition of “product” under the DSCSA in §581(13). Therefore nonsalable returns do not have to be accompanied by TI/TH/TS.

V. SUSPECT AND ILLEGITIMATE PRODUCT

27. The DSCSA does not require wholesale distributors to report suspect product. However, DSCSA does require wholesale distributors to report to FDA if a suspect product is determined NOT to be illegitimate (thus, implicitly notifying the FDA that the wholesale distributor had considered the product suspect in the first place). How should wholesale distributors address this apparent inconsistency in the law?

The DSCSA states that the wholesale distributor shall, upon clearing suspect product, provide notice to “the Secretary, if applicable.” §582(4)(A)(ii). A wholesale distributor can make an independent determination that a product is suspect, or it can find out about suspect product through a request for verification from the Secretary.\(^8\) Thus, the phrase “if applicable” in the statute should be read to mean that a wholesale distributor must notify the Secretary that suspect product is cleared (i.e., is NOT illegitimate) only when the investigation was initiated in response to a request for verification from the Secretary.

\(^8\)§582 (c)(4)(A)(i) “Upon making a determination that a product in the possession or control of a wholesale distributor is a suspect product, or upon receiving a request for verification from the Secretary that has made a determination that a product within the possession or control of a wholesale distributor is a suspect product...”
VI. 340B QUESTIONS

28. Does the DSCSA indicate to which entity a wholesale distributor should provide the TI/TH/TS data (i.e., transaction data) for drugs purchased under the federal Government’s 340B Drug Discount Program (“340B Program”)?

The DSCSA does not mention 340B Program drugs specifically. However, the DSCSA makes clear that when a wholesale distributor sells drugs, it must provide the transaction data to the party to which it transfers ownership of those drugs. In the case of sales made under the 340B Program (described further below), the wholesale distributor is transferring ownership of the drugs to so-called “Covered Entities” (“Covered Entities” or “CEs” such as hospitals) that are participating in the 340B Program. Thus, the plain language of the DSCSA would require the wholesale distributor to provide transaction data to each Covered Entity to which it sells (transfers ownership to) drug products.

As background, under the 340B Program, administered by the Health Resources and Services Administration (“HRSA”), wholesale distributors sell products to Covered Entities (typically hospitals). Some of the CEs contract with retail pharmacies (“Contract Pharmacies” or “CPs”) to provide dispensing services to 340B Program eligible patients. Sometimes, a CE will purchase products from its wholesale distributor and direct the wholesale distributor to ship the drugs directly to one of the Covered Entity’s Contract Pharmacies, which then dispenses the drugs to 340B eligible patients.

This “bill to/ship to” arrangement has caused some confusion regarding to which party the wholesale distributor should send the DSCSA-required transaction data. A plain reading of the DSCSA dictates that the wholesale distributor must provide the transaction data to the Covered Entity, the purchaser who is accepting ownership of the drugs from the wholesale distributor, regardless whether the drugs themselves are shipped to the Covered Entity’s CP.9

A coalition of CEs and CPs have taken the position that they would prefer for wholesale distributors to provide transaction data to Contract Pharmacies. The coalition petitioned FDA for an exemption from the DSCSA requirements that would permit wholesale distributors to send the transaction data to the CPs.10 As an accommodation to CEs and CPs, HDMA has supported the exemption request. HDMA’s support was conditioned on (1) the exemption being applied to all

---

9 A matrix describing the data that must be provided and a graphic depiction of this type of business model can be found in slides 5 and 7 of the HDMA “Transaction Scenarios” http://www.healthcaredistribution.org/~/media/pdfs/government-affairs/traceability-resource-2014-transaction-scenarios.ashx
340B Program ship to/bill to arrangements with the CP acting as the agent for the CE (that is, CEs/CPs could not pick and choose to whom the wholesale distributor would send the transaction data; all transaction data would be provided to the CPs), and (2) wholesale distributors being given adequate time to revise their data transmission processes to accommodate this exception to current practices.

**FDA has not yet responded to the CE /CP coalition’s exemption request.** Unless and until FDA responds, the clearest reading of the DSCSA requires wholesale distributors to continue to provide the transaction data to the CEs.

### VII. DISPENSER RELATED QUESTIONS

29. Are hospitals responsible for providing TI/TH/TS when they provide or sell drugs or drug products to emergency medical services (such as fire departments or ambulances)?

There are many factors that affect whether this transfer of ownership is covered by, or exempt from, the DSCSA’s TI/TH/TS data requirements.

The hospital would not have to provide transaction data if the transfer qualifies for one of the exemptions noted in the statutory definition of “transaction” at § 581(24)(B). These exemptions include, but are not limited to:

- Intracompany distributions between affiliates;
- Distributions by a dispenser to a healthcare entity under “common control” with it;
- Distribution for “emergency medical reasons including a public health emergency declaration...” (a distribution as a result of a drug shortage not caused by public health emergency does not qualify for this exemption);
- The product is a blood or blood component intended for transfusion (discussed in question 31 below);
- The seller is a charitable organization described in section 501(c)(3) of the Internal Revenue Code and the purchaser is a nonprofit affiliate of the seller; and
- The product is a medical convenience kit (discussed in question 32 below).

Another possible exclusion from the requirement to pass TI/TH/TS could exist if one dispenser sells to another dispenser to fill a “specific patient need.” The DSCSA defines “specific patient need” as:

the transfer of a product from one pharmacy to another to fill a prescription for an identified patient. Such term does not include the transfer of a product from one pharmacy...
to another for the purpose of increasing or replenishing stock in anticipation of a potential need. § 581(19). (emphasis added).

There are many forms that such transfers of ownership may take that are unique to a supply chain entity’s individual business model, practices and sales circumstances. Further, the DSCSA is very complex. HDMA urges any entity that believes it may not need to provide data in a product sale to review the DSCSA’s requirements with counsel to determine their data transmission responsibilities, if any.

VIII. EXEMPT PRODUCTS

30. What types of products are considered to be blood components and therefore exempt from DSCSA requirements?

The DSCSA requires TI/TH/TS to be passed/received when “products” are the subject of a “transaction” (i.e., change ownership). The law includes a number of exemptions from the definition of “product” and from “transaction.” Both the definition of “product” and “transaction” exempt “blood and blood components intended for infusion”. Thus, the transfer of ownership of blood and blood components (intended for infusion) does not trigger the requirement to pass or receive TI/TH/TS.

The DSCSA does not define further “blood and blood components”. Manufacturers of these types of products have made determinations as to whether their product is a blood product, blood component or other product that is exempt from DSCSA requirements. If you are unsure if a product is blood or a blood component intended for transfusion, or otherwise exempt from DSCSA requirements, we would recommend that you contact the manufacturer to find out how it has classified its product.

31. (a) Are medical devices exempt from DSCSA requirements? (b) Are combination products exempt from DSCSA requirements? (c) Are medical convenience kits exempt from DSCSA requirements?

(a) Medical devices are not included within the definition of “product”, and are thus transactions involving medical devices and not subject to DSCSA requirements.

(b) Combination products (e.g., medical device and a drug or biologic) are exempt from the DSCSA definition of “transaction” and thus their sale does not require the passage or receipt of TI/TH/TS as long as the combination product is not approved under an NDA, ANDA or BLA. Unless it is otherwise exempt, a prescription combination product approved under an NDA, ANDA or BLA would be covered by the DSCSA. If you are unsure if a product is covered by the DSCSA, contact the manufacturer to find out how it has classified its product.
(c) Finally, certain medical convenience kits also are exempt from the DSCSA definition of “transaction” (and thus exempt from the requirements to pass TI/TH/TS. Medical convenience kits qualifying for this exemption must meet a number of conditions, including that:

- The kit is assembled at a facility registered with FDA as a medical device manufacturer;
- The kit does not contain a controlled substance;
- If the kit contains a product, the kit manufacturer
  - Purchased the product from the manufacturer or a direct purchase wholesale distributor, and
  - Did not alter the label or primary container the product was packaged in;

And;

- The product contained in the kit is
  - An IV solution for replenishment of fluids and electrolytes;
  - Intended to maintain the equilibrium of water and minerals in the body;
  - Intended for irrigation or reconstitution; or
  - An anesthetic, anticoagulant, vasopressor, or sympathomimetic.

The DSCSA provisions regarding medical convenience kits and other products and transactions that are exempt from the DSCSA requirements are complicated. If you are unsure whether a product or transaction is exempt from DSCSA requirements, contact the manufacturer, which, in the case of a medical convenience kit, would be the entity that assembled the kit.

IX. DATA TRANSMISSION AND ASN-RELATED QUESTIONS

32. How should wholesale distributors handle shipping a discrepancy? Shortage, Damage, Overage?

FDA has not addressed discrepancies or the need for changes to correct information in TI/TH/TS. Certainly the DSCSA requires that accurate TI/TH/TS be passed, received and stored, so if errors are discovered, they need to be corrected. In the HDMA ASN Exceptions Guidelines for the Drug Supply Chain Security Act (“ASN Exceptions Guidelines”), HDMA describes various scenarios in which there is a discrepancy or error in TI/TH/TS, and proposed responses/corrective actions.
33. If a wholesale distributor receives more product than it receives data for (e.g., it orders 150 units but only receives TI/TH/TS for 100 units), how does the wholesale distributor handle the 50 units for which it does not have data? How should the manufacturer correct the missing data?

The DSCSA provides that a wholesale distributor may not accept ownership of a product (that is, accept product into inventory) unless, prior to or at the time of product receipt, it has also received sufficient transaction data (TI/TH/TS). So, in the above example, the wholesale distributor could accept ownership of 100 units because it received transaction data for 100 units. Before the wholesale distributor could accept ownership of the final 50 units, the manufacturer would need to send the transaction data for those 50 units to the wholesale distributor. The ASN Exceptions Guidelines addresses this and other discrepancy issues in more detail.

34. If a wholesale distributor receives less product than it receives data for (e.g., it orders 300 and receives TI/TH/TS for 300 units but only 200 units are shipped), how should the wholesale distributor handle the discrepancy? How should the manufacturer correct the missing units ordered?

As noted elsewhere in these responses, the DSCSA prohibits a wholesale distributor from accepting ownership of a product unless it has received sufficient transaction data. In the present example, the wholesale distributor received transaction data for the 200 units shipped, so the wholesale distributor may accept ownership of the 200 units. For the quantity not shipped, the parties would use standard business practices to resolve the shortage. The ASN Exceptions Guidelines addresses this and other discrepancy issues in more detail.

35. For a particular transaction, Company Y is the seller and the “ship from” within the TI, and Company X is the buyer and the “ship to”. In the ASN, does Company Y need to send the information in four different segments or can Company Y just send it in two segments?

Company Y should send all four segments, even if the information is the same. In the ASN Guidelines, HDMA intentionally created this structure to make clear (i) the buyer and seller information for DSCSA compliance, and (ii) the logistical movement of product. Even though the buyer and “ship to” are the same in this scenario, the buyer is not the same entity as the “ship to” in all transactions.

36. Has FDA approved of the transaction statement language used in HDMA’s ASN Guidelines?

HDMA’s legal interpretation is that the example language in the ASN Guidelines is sufficient. The transaction statement can be sent or exchanged in one Yes/No Question (“YNQ”) segment per the guidelines.\(^{11}\)

---

\(^{11}\) Please contact HDMA’s Industry Relations team for more technical detail on ASN segments at 703-787-0000.
37. Can you use more than one YNQ segment in the ASN to provide the transaction statement?

HDMA recommends that trading partners use one YNQ segment for the TS.\(^\text{12}\)

38. Has FDA approved of the direct purchase statement language in HDMA’s ASN Guidelines?

HDMA’s legal interpretation is that the language in the ASN Guidelines is sufficient.\(^\text{13}\)

39. My shipment contains items that are exempt from DSCSA. Can I use the same ASN?

Yes you can; however, you only need to send TI/TH/TS for products covered by DSCSA. Distributors typically ‘flag’ exempt items in their internal systems based on information from the manufacturer for each product. (For example, manufacturers will be prompted when completing the HDMA Standard Product Information Form for Pharmaceutical Products [the ‘HDMA New Item Form’] to indicate if that particular product is exempt from DSCSA requirements.)

40. Where in the ASN is the transaction date identified?

In the ASN, there is a spot at the Beginning Segment for Ship Notice (BSN) segment for transaction date. The date the trading partners choose as the ownership transfer date should be inserted there by the seller.

41. Would an ASN from a manufacturer include more than one product/different lots, etc.? If there are different products/different lots, do they provide the TS at the item/line level?

Yes, an ASN can still accommodate multiple products and different lots. There is line item detail which can provide a TS, including direct purchase statements and other detailed information (name, NDC#, lot #, container size, number of containers, etc.) about the product. The TS at the shipment level directs the receiver to line level for detailed direct purchase statements.

42. Does TH require only an additional N1 loop or a new ASN attached to the previous one in the chain?

HDMA believes that all of the required information can be sent in the one ASN between the two trading partners. Furthermore, the ASN does not have the capability to “follow” a single product or single lot through the supply chain. Each shipment generates a new ASN. For example, the manufacturer generates an ASN for a case of drug product; the ASN and the product are then provided to the purchasing wholesale distributor. Once the case is received, the wholesale distributor typically removes the individual units from the case and warehouses them. For its

\(^{12}\text{Ibid.}\)

\(^{13}\text{Ibid.}\)
customers, the wholesale distributor then creates a new ASN, from the wholesale distributor to the dispenser, to accompany the shipment that identifies all of the different drugs, from all of the different suppliers, and other relevant shipment information.

43. What will the receiving party do if an ASN is not received at the time the shipment arrives at the receiving party’s dock? Hold-off on formal receipt?

The law states that “A wholesale distributor shall not accept ownership of a product unless the previous owner prior to, or at the time of, the transaction provides the transaction history, transaction information, and a transaction statement for the product, as applicable under this subparagraph.” § 582(c)(1)(A)(i). This means that the wholesale distributor must have TI/TH/TS at the time of or before the change of ownership. Trading partners will need to determine how the seller will provide TI/TH/TS to the receiving party (whether by paper, ASN or other form) so that the receiving party may accept ownership of the product.

Because the time at which an ownership change occurs varies based upon commercial agreements between the parties, if product were to arrive at a buyer’s warehouse without TI/TH/TS, holding off on the physical receipt of product would be a business decision of the individual trading partners. Certainly if the buyer physically receives the product prior to receiving TI/TH/TS, the goods would need to remain quarantined until receipt of TI/TH/TS so that ownership could lawfully be accepted. See HDMA’s ASN Exceptions Guidelines for more details.

44. If Distributor X does not supply the lot number to Distributor Y, how should Distributor Y pass that information to the dispenser?

Distributor Y should check the label of the product for the lot number, which is usually included on the unit-level product’s external packaging, and/or on the label affixed to the bottle. HDMA has identified the DSCSA required transaction data for different transaction scenarios among trading partners. This information can be found in the HDMA Transaction Scenarios.

45. If the “ship to” and “bill to” addresses are different for a dispenser, does the wholesale distributor need to show both addresses in the transaction data?

No. The DSCSA requires a seller to provide TI to the buyer. The law specifies that the TI must include “the business name and address of the person to whom ownership is being transferred” (i.e., the buyer). When the seller provides TI/TH/TS data in an electronic Advance Ship Notice (ASN) or on other transmission documents, such as invoices or packing slips, the purchaser’s address is referred to as the “bill to” address. In some cases, the “bill to” addresses for the purchaser is different from the physical location – or “ship to” address – where a product is being delivered.
For business reasons, many buyers and sellers also provide this “ship to” address to the purchaser. If the “bill to” and “ship to” addresses are different -- for example, if the purchaser’s main business office handling the transaction’s payment is in a hospital’s main building, but the product will be physically delivered, stored and used in a separate outpatient department -- the recipient will likely receive both a “bill to” address and a “ship to” address reflecting each separate address. Note that if a “bill to” address and a “ship to” address are different locations, the DSCSA does not require retention of the “ship to” address (which is not part of the TI).

X. EXCEPTIONS TO TRANSACTION DATA REQUIREMENTS

46. Are free-of-charge items subject to TI/TH/TS requirements? There is change of ownership but no exchange of money.

There are a variety of scenarios under which products change ownership, but do not trigger the requirement for passing TI/TH/TS. Specifically, if the transfer of goods is exempt from the statutory definition of “transaction” (§581(24)), then the change in ownership does not trigger the TI/TH/TS requirement (similarly, if the distribution of product is excluded from the statutory definition of “wholesale distribution” (new FDCA § 503(e)(4)), TI/TH/TS would not be required to be passed/received). For example, the distribution of product samples by a manufacturer or licensed wholesale distributor is exempt from the definition of “transaction” (§ 581(24)(B)(v)) and, therefore, the transfer of samples would not need to be accompanied with TI/TH/TS.

47. Are donated items subject to TI/TH/TS requirements? There is a change of ownership but no exchange of money.

As noted in the response to the previous question, if the distribution of product is excluded from the statutory definition of “transaction” or “wholesale distribution”, TI/TH/TS would not be required to be passed/received. For example:

- Charitable Organizations: The distribution of product by a 501(c)3 charitable organization to a non-profit affiliate is exempt from the definition of “transaction” (§ 581(24)(B)(viii)). [Please note that the transfer of ownership from a manufacturer (or wholesale distributor) to a charitable organization – even if the product is donated – would constitute a “transaction” and, therefore, the transfer would require the transmission of TI/TH/TS.]
- Specific Types of Products and Specific Parties: The definition of “transaction” excludes the distribution of a number of types of products (e.g., convenience kits that contain certain specified drugs), regardless of the parties involved in the transfer, as well as distributions to specific parties (e.g., transfers among affiliates, or transfers to or from a facility licensed by the Nuclear Regulatory Commission), regardless of the product involved. Please see §581(24)(B) for details.
48. Are products designated for destruction subject to TI/TH/TS requirements? There is a change of ownership but no exchange of money.

Products designated for destruction are covered by the DSCSA’s “nonsalable returns” provisions. Under DSCSA, the transfer of product by a manufacturer, wholesale distributor or dispenser (with or without the use of a returns processor) for destruction is exempt from the requirements to pass TI/TH/TS.

49. Are items distributed for emergency medical reasons subject to TI/TH/TS requirements?

The distribution of product for emergency medical reasons (which does not include a drug shortage) is exempt from the definition of “transaction” (§ 581(24)(B)(iii)), and thus exempt from the requirements to pass TI/TH/TS.

XI. GRANDFATHERED PRODUCT

50. What are a wholesale distributor’s obligations with respect to passing TI/TH/TS for product that was received prior to January 1, 2015*, but sold after January 1, 2015*?

[NOTE 4: FDA’s guidance mentioned in Note 2 above does not specifically address how, if at all, the “grandfathering” provision of the DSCSA (discussed further below) would be affected, but the only logical assumption is that the provision would be affected because it addresses product tracing requirements.

Accordingly, while the response below includes the statutory implementation date of January 1, 2015, FDA should agree that the “cut-off date” for grandfathered product is now May 1, 2015. For consistency, HDMA has continued to use the statutory deadline of January 1, 2015 (with an asterisk) which can be read as May 1, 2015 if the guidance applies to grandfathering.]

Starting January 1, 2015*, the DSCSA requires a seller to pass transaction data (TI/TH/TS) when it transfers ownership of its drug products. The DSCSA includes a provision (entitled, “Grandfathering Product”) that describes the TI/TH/TS requirements for products entering the supply chain before January 1, 2015*. [See section 582(a)(5)(B)] With respect to transaction data requirements, this provision provides as follows:

For a product that entered the pharmaceutical distribution supply chain prior to January 1, 2015*—

(i) authorized trading partners shall be exempt from providing transaction information as required under subsections (b)(1)(A)(i), (c)(1)(A)(ii), (d)(1)(A)(ii), and (e)(1)(A)(ii) [these are
citations to the transaction data requirements for manufacturers, direct purchase wholesale distributors, dispensers and repackers, respectively];

(ii) transaction history required under this section shall begin with the owner of such product on such date; and

(iii) the owners of such product on such date shall be exempt from asserting receipt of transaction information and transaction statement from the prior owner as required under this section.

This section of the DSCSA is not particularly clear, and in the absence of any FDA guidance, we interpret this provision to mean:

Prior to January 1, 2015*:

- When engaging in wholesale distribution of a drug, a company must comply with the requirements of the Prescription Drug Marketing Act (PDMA) and pass a pedigree when appropriate.

Starting January 1, 2015*, for any drug that entered the supply chain prior to January 1, 2015*:

- The entity that owns the product on January 1, 2015* is not required to pass, receive or store any transaction data that it was not required to receive.

When engaging in a new transaction after January 1, 2015*:

- It is not clear from the statutory provision set forth above whether the seller is required to pass TI. Because TI can be generated by the seller in a new transaction and is not dependent on the information that the seller received prior to January 1, 2015* for the product, FDA likely would interpret the statutory provision as requiring the seller to pass TI.

- The seller must pass TH, but the TH can start with the entity that owns the product on January 1, 2015*.

- The entity that owns the product on January 1, 2015* must pass TS when it sells the drug, but is not required to assert that it received TI and TS from the prior owner (two of the elements of a full TS). All subsequent owners must pass full TS.